Roles of IDH1/2 and TET2 mutations in myeloid disorders

Satoshi Inoue; François Lemonnier; Tak W Mak

doi:10.1007/s12185-016-1973-7

Roles of IDH1/2 and TET2 mutations in myeloid disorders

Int J Hematol. 2016 Jun;103(6):627-33. doi: 10.1007/s12185-016-1973-7. Epub 2016 Mar 15.

Authors

Satoshi Inoue¹, François Lemonnier¹, Tak W Mak²

Affiliations

¹ The Campbell Family Institute for Breast Cancer Research, Princess Margaret Cancer Centre, Ontario Cancer Institute, University Health Network, 610 University Avenue, Toronto, ON, M5G 2M9, Canada.
² The Campbell Family Institute for Breast Cancer Research, Princess Margaret Cancer Centre, Ontario Cancer Institute, University Health Network, 610 University Avenue, Toronto, ON, M5G 2M9, Canada. tmak@uhnresearch.ca.

PMID: 26980223
DOI: 10.1007/s12185-016-1973-7

Abstract

Mutations of the epigenetic enzymes isocitrate dehydrogenase (IDH) 1 and 2, and the methylcytosine dioxygenase 'ten-eleven translocation 2' (TET2), are common in human myeloid malignancies and drivers of these disorders but the underlying mechanisms remain obscure. This review examines mutant IDH1/2 and TET2 enzymes in the context of responses to DNA damage and their potential involvement in age-related genomic instability. The clinical relevance of these findings and their potential application in novel therapeutic strategies is also discussed.

Keywords: AML; DNA damage; DNA repair; IDH1; MDS; TET2.

Publication types

Review

MeSH terms

DNA Damage
DNA-Binding Proteins / genetics*
Dioxygenases
Genomic Instability
Humans
Isocitrate Dehydrogenase / genetics*
Mutation / physiology*
Myeloproliferative Disorders / genetics*
Proto-Oncogene Proteins / genetics*

Substances

DNA-Binding Proteins
Proto-Oncogene Proteins
IDH2 protein, human
Isocitrate Dehydrogenase
IDH1 protein, human
Dioxygenases
TET2 protein, human